Commission Implementing Decision of 24 April 2014 concerning a Union financial contribution towards surveillance and other emergency measures implemented in Estonia, Latvia, Lithuania and Poland against African swine fever (notified under document C(2014) 2551) (Only the Estonian, Latvian, Lithuanian and Polish texts are authentic) (2014/236/EU)

Article 2 U.K.

1. The maximum of the costs to be reimbursed to the Member States referred to in Article 1(1) for the activities referred to in Article 1(2) points (a), (b), (c) and (d) shall on average not exceed:

(a) EUR 0,5 per domestic pig sampled;

(b) EUR 5 per wild boar sampled;

(c) EUR 2 per ELISA test;

(d) EUR 10 per PCR and Sequencing test.

2. The maximum of the costs to be reimbursed for the activity referred to in Article 1(2) point (e) shall on average not exceed:

(a) EUR 6 000 for Estonia;

(b) EUR 58 000 for Latvia;

(c) EUR 950 000 for Lithuania;

(d) EUR 102 100 for Poland.

3. The maximum of the costs to be reimbursed for the activity referred to in Article 1(2) point (f) shall not exceed:

(a) EUR 100 000 for Lithuania;

(b) EUR 150 000 for Poland.

4. The maximum of the costs to be reimbursed for the activity referred to in Article 1(2) point (g) shall not exceed:

• EUR 75 000 for Lithuania.

5. The maximum of the costs to be reimbursed for the activity referred to in Article 1(2) point (h) shall on average not exceed:

(a) EUR 1 500 for Estonia;

(b) EUR 15 000 for Latvia;

(c) EUR 75 000 for Lithuania;

(d) EUR 11 250 for Poland.

6. The financial contribution by the Union to the Member States referred to in Article 1(3) shall not exceed:

(a) EUR 225 000 for Lithuania;

(b) EUR 337 500 for Poland.

7. The financial contribution by the Union to the Member States referred to in Article 1(1) shall not exceed:

(a) EUR 27 000 for Estonia;

(b) EUR 190 000 for Latvia;

(c) EUR 1 948 000 for Lithuania;

(d) EUR 1 341 000 for Poland.

8. The expenditure eligible for a financial contribution by the Union for the measures referred to in points c) and d) of paragraph 1 shall be limited to the costs incurred by the Member States for:

(a) the purchase of test kits, reagents and all consumables identifiable and especially used for carrying out the laboratory tests;

(b) personnel, whatever the status, specifically allocated entirely or in part for carrying out the tests in the premises of the laboratory, limited to actual salaries plus social security charges and other statutory costs included in the remuneration;

(c) overheads equal to 7 % of the sum of the costs referred to in (a) and (b).